Back to top
more

Integer Holdings (ITGR)

(Delayed Data from NYSE)

$106.52 USD

106.52
379,870

-1.99 (-1.83%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $106.51 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (159 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

XRAY Stock Gains Post Q1 Earnings & Revenue Beat, Gross Margin Down

by Zacks Equity Research

DENTSPLY SIRONA's customer-centric innovation and operational efficiency drive its first-quarter 2025 performance despite global macroeconomic challenges.

Zacks Equity Research

Phibro Q3 Earnings Top Estimates, Stock Up, 2025 EPS Outlook Raised

by Zacks Equity Research

PAHC's third-quarter fiscal 2025 results reflect the strength of the Animal Health segment.

Zacks Equity Research

Bruker Q1 Earnings & Revenues Top Estimates, Stock Up, Margins Crash

by Zacks Equity Research

Bruker delivers better-than-expected earnings and revenues in the first quarter of 2025.

Zacks Equity Research

EYE Q1 Earnings and Revenues Beat, Gross Margin Up, Stock Surges

by Zacks Equity Research

Continued strength in Managed Care aids National Vision's first-quarter 2025 performance.

Zacks Equity Research

QGEN Q1 Earnings and Revenues Top, Operating Margin Expands, Stock Up

by Zacks Equity Research

QGEN's quarterly performance benefits from a resilient portfolio in the first quarter of 2025.

Zacks Equity Research

AVNS Stock Gains Post Q1 Earnings & Revenue Beat, Gross Margin Down

by Zacks Equity Research

Strength in Avanos' SNS segment drives its first-quarter 2025 performance despite global macroeconomic challenges.

Zacks Equity Research

FMS Stock Up as Q1 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Fresenius Medical's first-quarter results showcase a strong segmental performance, along with reiterating its 2025 outlook for revenue growth.

Zacks Equity Research

CLOV Stock Rises as Q1 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Clover Health's first-quarter 2025 results continue to benefit from the strength of its strong member retention. A decline in operating loss bodes well.

Zacks Equity Research

MASI Stock Slips Despite Q1 Earnings and Revenue Beat, Margins Expand

by Zacks Equity Research

Masimo's first-quarter 2025 results continue to benefit from the strength in its Healthcare businesses despite tariff-related uncertainties.

Zacks Equity Research

Bio-Techne Q3 Earnings & Revenues Top Estimates, Stock Up in Premarket

by Zacks Equity Research

TECH registers continued growth momentum across its Diagnostics & Spatial Biology segment in third-quarter fiscal 2025.

Zacks Equity Research

CRL Q1 Earnings & Revenues Beat Estimates, Stock Rises, '25 View Up

by Zacks Equity Research

Charles River delivers better-than-expected earnings and revenues in the first quarter of 2025.

Zacks Equity Research

MYGN Q1 Earnings Top Estimates, Stock Down on Weak 2025 Outlook

by Zacks Equity Research

Myriad Genetics delivers a narrower-than-expected loss in the first quarter of 2025.

Zacks Equity Research

HIMS Stock Dips Pre-Market Despite Q1 Earnings Beat, Gross Margin Down

by Zacks Equity Research

Hims & Hers' first-quarter 2025 performance reflects continued strength in its online revenue channel on the back of solid product demand and an increasing subscriber base.

Zacks Equity Research

INSP Stock Gains Following Q1 Earnings Beat, Gross Margin Contracts

by Zacks Equity Research

Inspire Medical's first-quarter 2025 performance reflects increased market penetration in existing centers and expansion into new territories and centers, along with strong domestic results.

Zacks Equity Research

ITGR or SONVY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ITGR vs. SONVY: Which Stock Is the Better Value Option?

Zacks Equity Research

Wall Street Analysts Think Integer (ITGR) Could Surge 29.03%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 29% in Integer (ITGR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Integra Q1 Earnings Miss Estimates, Stock Down, '25 EPS Outlook Cut

by Zacks Equity Research

IART's first-quarter 2025 earnings lag the consensus mark. Q2 revenue projections are bleak.

Zacks Equity Research

Henry Schein Q1 Earnings Top Estimates, Revenues Miss, Stock Falls

by Zacks Equity Research

HSIC ends the first quarter of 2025 on a mixed note.

Zacks Equity Research

EXAS Stock Up on Q1 Earnings & Revenue Beat, 2025 Sales View Raised

by Zacks Equity Research

Exact Sciences ends the first quarter of 2025 on a solid note.

Zacks Equity Research

Hologic Q2 Earnings & Revenues Top, '25 EPS View Lowered, Stock Down

by Zacks Equity Research

HOLX delivers earnings and revenue beat in the second quarter of fiscal 2025 amid macroeconomic turbulence.

Zacks Equity Research

SRDX Stock Down Following Q2 Earnings Miss, Gross Margin Contracts

by Zacks Equity Research

Despite the strength in Pounce thrombectomy device platforms and strong IVD product sales, Surmodics' second-quarter fiscal 2025 results show weak performance.

Zacks Equity Research

OPK Stock Slips Following Q1 Earnings Miss, Gross Margin Expands

by Zacks Equity Research

Despite strength in OPKO Health's revenues from the transfer of intellectual property, the company reports an overall soft first-quarter 2025 performance.

Zacks Equity Research

BD Stock Falls in Pre-Market Despite Q2 Earnings Beat, Margins Down

by Zacks Equity Research

BDX's overall topline in the second quarter of fiscal 2025 continues to benefit from strength in its Medical segment and geographic performances.

Zacks Equity Research

ICON's Q1 Earnings Surpass Estimates, Revenues Lag, Stock Down

by Zacks Equity Research

ICLR posts mixed results in the first quarter of 2025 due to ongoing clinical development and market volatility.